Pharmaceutical giant Eli Lilly and Company has announced a partnership with artificial intelligence-focused biotechnology company Profluent in a deal valued at up to $2.25 billion, marking another significant investment in AI-driven drug development.

The collaboration focuses on genetic medicine applications, leveraging Profluent's artificial intelligence capabilities to advance drug discovery and development processes. The partnership represents Lilly's continued expansion into AI-assisted pharmaceutical research as the industry increasingly adopts machine learning technologies to accelerate drug development timelines.

Profluent specializes in using artificial intelligence to design and optimize therapeutic compounds, particularly in the genetic medicine space. The company's AI platform aims to streamline the traditionally lengthy and expensive process of bringing new medications to market.

The deal structure includes milestone payments and potential future earnings based on successful development and commercialization of products emerging from the partnership. This arrangement is typical in pharmaceutical collaborations, where payments are tied to achieving specific research, development, and regulatory milestones.

The partnership comes as pharmaceutical companies are increasingly investing in AI technologies to enhance their drug discovery capabilities and reduce development costs. Major pharmaceutical firms have been forming similar alliances with AI-focused biotechnology companies as they seek to maintain competitive advantages in drug development.